Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial
International Journal of Infectious Diseases (2021) - Comments
pubmed: 33212256  doi: 10.1016/j.ijid.2020.11.142  issn: 1201-9712  issn: 1878-3511 

Zarir F. Udwadia, Pawan Singh, Hanmant Barkate, Saiprasad Patil, Shabbir Rangwala, Amol Pendse, Jatin Kadam, Wen Wu, Cynthia F. Caracta, Monika Tandon